SwedenSweden

SBL Buys Back its own Shares

07.06.2004

Stockholm - SBL's executive management, in co-operation with venture capitalist 3i and the banking group SEB Företags-invest, have recently established a jointly owned company and acquired all shares in SBL Vaccin AB (SBL) from Chiron Vaccines, a business unit of the US-based Chiron Corporations Inc. SBL will be developed as an independent company under industry-neutral ownership. Financial details were not disclosed.
“It is incredibly exciting and a huge responsibility to take control of SBL's future development,” says Björn Sjöstrand, CEO of SBL, who worked with Mats Lidgard, executive vice president, as the driving force behind the management buy-out. “We believe SBL has significant potential for continued business expansion,” says Thomas Pollare, Investment Director of 3i Sweden. SBL develops, manufactures, markets and distributes vaccines. The company's products include Dukoral®, an oral vaccine against cholera which is also used to prevent travelers' diarrhoea. Dukoral has been sold in Sweden and Norway for years and was recently approved for sale in all EU countries.
“The reason that Chiron Vaccines is selling SBL is that its operations are not aligned with our strategic pursuits. SBL is a market leader in Sweden and its main co-operation partners are companies that compete with Chiron Vaccines,” explained John Lambert, President of Chiron Vaccines. Under terms of the agreement, the UK company will market Dukoral in some of the most important markets in Europe.

SwedenSweden

14.04.2011

Stockholm – Swedish Orphan Biovitrum AB (SOBI) has reported weak results for 2010. The company’s net income declined by 7.7% to SEK1.9bn, with losses for the period totalling up to SEK104m. SOBI spokesmen said that several...

SwedenSweden

06.04.2011

Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR...

SwedenSweden

08.02.2011

Stockholm – At the end of last year, the first European patient was treated with Ruconest – a recombinant C1 esterase inhibitor for the treatment of hereditary acute angioedema attacks developed by the Dutch Pharming Group NV and...

SwedenSweden

10.12.2010

Lund/Jerusalem – Active Biotech’s oral small molecule immunomodulator laquinimod (ABR-215062) has reached the primary endpoint of statistically significant reduction in annualized relapse rate compared to placebo, according to...

SwedenSweden

04.11.2010

Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the...

SwedenSweden

25.10.2010

Stockholm - Swedish researchers have unravelled the three-dimensional structure of the egg receptor, paving the way for new treatments of infertility and novel contraceptives. The team headed by Luca Jovine at Karolinska...

SwedenSweden

16.09.2010

Uppsala – Orexo AB has announced a bold new strategy. The company listed on the Stockholm stock exchange intends to develop and commercialise its own products from now on rather than out-licensing them to international partners....

SwedenSweden

15.09.2010

Linköping – In the first clinical study of its kind, Swedish researchers have proven that biosynthetic corneas can offer a real alternative to rare human replacement corneas. In a process developed by Per Fagerholm and May...

Displaying results 21 to 30 out of 182

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/2/article/sbl-buys-back-its-own-shares.html

Product of the week

Products

Events

All Events

Current issue

All issues